Optimizing Enhertu Prior Authorization for Cardiology Practices

The Prior Authorization Landscape for Specialty Drugs in Cardiology

Enhertu, like many advanced therapies, is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. While primarily an oncology medication, its administrative burden mirrors that of specialty cardiovascular drugs, which also face rigorous PA requirements within cardiology. This includes PCSK9 inhibitors, sacubitril/valsartan, and SGLT2 inhibitors for heart failure indications, all requiring detailed clinical justification.

Key Documentation for Cardiology Specialty Drug PAs

• Diagnosis and specific indication for therapy.
• Functional status (e.g., NYHA class for heart failure, as applicable).
• History of prior pharmacotherapy, including trials of optimal medical therapy and any intolerance or contraindications.
• Relevant diagnostic test results (e.g., ejection fraction, LDL levels, genetic testing).
• Adherence to established clinical guidelines (e.g., ACC/AHA) where applicable to the drug class.

Common Prior Authorization Denials for Specialty Drugs in Cardiac Care

Denial reasons for specialty drug prior authorizations in cardiology often stem from a lack of specific documentation or non-adherence to payer policies. Common issues include failure to demonstrate an adequate trial of step-therapy medications, insufficient documentation of guideline-directed medical therapy duration, and gaps in documenting specific diagnostic criteria such as ejection fraction or LDL levels as required for the drug’s indication.

Klivira's Approach to Streamlining Specialty Drug Prior Authorization in Cardiology

Klivira’s platform is engineered to navigate the complexities of specialty drug prior authorization within cardiology. By integrating with EMRs and connecting to a vast network of payer portals and specialty benefit-management vendors, Klivira automates the submission process. This includes identifying whether a request routes to a vendor like Carelon MBM or eviCore (successor vendors) for advanced imaging, or payer-direct for specialty drugs like PCSK9 inhibitors, sacubitril/valsartan, or other high-volume PA targets like Enhertu, applying relevant policy logic.

Integrating Klivira for Enhanced Cardiology PA Workflows

Integrating Klivira into cardiology workflows addresses several specialty-specific constraints. The platform streamlines the often time-sensitive PA for urgent presentations by expediting submissions. It manages the prevalence of specialty benefit-management vendors by providing a unified interface, and its automated logic helps ensure all required documentation, such as guideline adherence or prior therapy history, is captured before submission, reducing rework and improving approval rates for specialty drugs.